Literature DB >> 21914427

Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms.

Ugur Kuyumcuoglu1, Bilal Eryildirim, Murat Tuncer, Gokhan Faydaci, Fatih Tarhan, Aydin Ozgül.   

Abstract

BACKGROUND: We investigated whether the frequency of lower urinary tract symptoms (LUTS) increased in patients in whom double-J stents were applied. We also evaluated several medical therapy protocols to treat symptoms related with ureteral stents.
MATERIALS AND METHODS: A total of 108 patients, in whom unilateral double-j stent was applied during ureteral stone treatment, were included. Before the double-J stent was applied, all patients completed storage components of the "International Prostate Symptom Score" (IPSSs), quality of life components of the IPSS (IPSS-QOL) and "Overactive Bladder Questionnaire" (OABq) forms and scores were calculated. After the procedure, cases were randomized into 5 groups, an antiinflammatory was given to Group 1, spasmolytic to Group 2, anticholinergic to Group 3 and α-blocker to Group 4. No additional drug was given to Group 5 as this control group. During the fourth week of the procedure, IPSSs, IPSS-QOL and OABq forms were again completed and scores were compared with the previous ones.
RESULTS: When all the cases were evaluated, the IPSSs, IPSS-QOL and OABq scores of patients in whom the double-J stent was applied were statistically significantly higher the procedure. Compared to the control group, the cases where the double-J stent was applied showed a higher IPSSs, IPSS-QOL and OABq scores and none of the medical therapies could prevent this increase.
INTERPRETATION: The frequency of LUTS increased in cases where the ureteral stent was applied and discomfort continued as long as the stent stayed in the body.

Entities:  

Year:  2011        PMID: 21914427      PMCID: PMC3529727          DOI: 10.5489/cuaj.10143

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  16 in total

1.  Does the size of ureteral stent impact urinary symptoms and quality of life? A prospective randomized study.

Authors:  Rocco Damiano; Riccardo Autorino; Marco De Sio; Francesco Cantiello; Giuseppe Quarto; Sisto Perdonà; Rosario Sacco; Massimo D'Armiento
Journal:  Eur Urol       Date:  2005-10       Impact factor: 20.096

2.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

3.  Is there a role for alpha1-blockers in treating double-J stent-related symptoms?

Authors:  Charalambos Deliveliotis; Michael Chrisofos; Evagelos Gougousis; Athanasios Papatsoris; Athanasios Dellis; Ioannis M Varkarakis
Journal:  Urology       Date:  2006-01       Impact factor: 2.649

4.  Have stent-related symptoms anything to do with placement technique?

Authors:  A Rane; A Saleemi; D Cahill; S Sriprasad; N Shrotri; R Tiptaft
Journal:  J Endourol       Date:  2001-09       Impact factor: 2.942

5.  Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.

Authors:  K Coyne; D Revicki; T Hunt; R Corey; W Stewart; J Bentkover; H Kurth; P Abrams
Journal:  Qual Life Res       Date:  2002-09       Impact factor: 4.147

6.  Indwelling ureteral stents and sexual health: a prospective, multivariate analysis.

Authors:  M C Sighinolfi; S Micali; S De Stefani; A Mofferdin; M Grande; A Grande; M Giacometti; N Ferrari; M Rivalta; G Bianchi
Journal:  J Urol       Date:  2007-05-17       Impact factor: 7.450

7.  A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort.

Authors:  Regina D Norris; Roger L Sur; W Patrick Springhart; Charles G Marguet; Barbara J Mathias; Paul K Pietrow; David M Albala; Glenn M Preminger
Journal:  Urology       Date:  2008-03-12       Impact factor: 2.649

8.  Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study.

Authors:  Richard Beddingfield; Renato N Pedro; Bryan Hinck; Carly Kreidberg; Kendall Feia; Manoj Monga
Journal:  J Urol       Date:  2008-11-14       Impact factor: 7.450

Review 9.  Minimizing symptoms in patients with ureteric stents.

Authors:  Mordechai Duvdevani; Ben H Chew; John D Denstedt
Journal:  Curr Opin Urol       Date:  2006-03       Impact factor: 2.309

10.  Early and late complications of double pigtail ureteral stent.

Authors:  Rocco Damiano; Andrea Oliva; Ciro Esposito; Marco De Sio; Riccardo Autorino; Massimo D'Armiento
Journal:  Urol Int       Date:  2002       Impact factor: 2.089

View more
  11 in total

1.  The role of pregabalin in relieving ureteral stent-related symptoms: a randomized controlled clinical trial.

Authors:  Maged Ragab; Mohamed G Soliman; Ahmed Tawfik; Ali Abdel Raheem; Hassan El-Tatawy; Mohamed Abo Farha; Michael Magdy; Osama Elashry
Journal:  Int Urol Nephrol       Date:  2017-03-04       Impact factor: 2.370

2.  α1-blockers for the reduction of ureteric stent-related symptoms: A systematic review and meta-analysis.

Authors:  Peng Zhang; Wan-Li Hu; Bei Cheng; Long Cheng; Yang-Jun Zeng; Gang Wang
Journal:  Exp Ther Med       Date:  2015-12-16       Impact factor: 2.447

3.  A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent-related symptoms: a 2 × 2 factorial randomized trial.

Authors:  Jinsung Park; Changhee Yoo; Deok Hyun Han; Dong Wook Shin
Journal:  World J Urol       Date:  2015-03-26       Impact factor: 4.226

4.  Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms.

Authors:  Mohamed H Abdelhamid; Ahmed S Zayed; Waleed E Ghoneima; Akrm A Elmarakbi; Mohamed S El Sheemy; Ahmed Aref; Ahmed Abdelbary; Hani H Nour
Journal:  World J Urol       Date:  2017-01-03       Impact factor: 4.226

5.  Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms-outcomes from a network meta-analysis.

Authors:  Zhongyu Jian; Yuntian Chen; Qinyu Liu; Banghua Liao; Tongxin Yang; Hong Li; Kunjie Wang
Journal:  World J Urol       Date:  2018-07-20       Impact factor: 4.226

6.  Spontaneous fracture of indwelling polyurethane ureteral stents: A case series and review of literature.

Authors:  Michael E Chua; Marcelino L Morales
Journal:  Can Urol Assoc J       Date:  2012-10       Impact factor: 1.862

7.  Efficacy of α-blocker in improving ureteral stent-related symptoms: a meta-analysis of both direct and indirect comparison.

Authors:  Feng He; Li-Bo Man; Gui-Zhong Li; Ning Liu
Journal:  Drug Des Devel Ther       Date:  2016-05-26       Impact factor: 4.162

8.  PRISMA-combined α-blockers and antimuscarinics for ureteral stent-related symptoms: A meta-analysis.

Authors:  Yu-Ming Zhang; Pei Chu; Wen-Jin Wang
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

9.  The role of mirabegron in relieving double-J stent-related discomfort: a randomized controlled clinical trial.

Authors:  Ehab Galal; Mohamed H Abdelhamid; Tarek Fath El-Bab; Amr Abdelhamid
Journal:  Cent European J Urol       Date:  2021-02-12

10.  Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-j stent-related lower urinary symptoms.

Authors:  Essam Shalaby; Abul-Fotouh Ahmed; Aref Maarouf; Iman Yahia; Mohamed Ali; Ammar Ghobish
Journal:  Adv Urol       Date:  2013-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.